N@N

Eli Lilly, Andreessen Horowitz link up on $500M biotech venture fund

Eli Lilly and the venture capital firm Andreessen Horowitz have partnered to launch a $500 million fund aimed at investing in early-stage biotech companies. This collaboration seeks to combine Lilly's deep expertise in drug development with Andreessen Horowitz's extensive experience in technology and venture capital to foster innovation in the biotech sector. The fund will focus on supporting startups that are developing groundbreaking therapies, particularly those leveraging cutting-edge technologies like gene editing, RNA therapies, and AI-driven drug discovery. This initiative not only aims to accelerate the pace of bringing new treatments to market but also to potentially yield significant returns for both Lilly and Andreessen Horowitz through equity stakes in promising biotech ventures.

Read the Full FierceBiotech Article at:
[ https://www.fiercebiotech.com/biotech/eli-lilly-and-andreessen-horowitz-link-500m-biotech-venture-fund ]